Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;26(4):409-420.
doi: 10.1007/s11912-024-01503-y. Epub 2024 Mar 19.

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Michael Wysota  1 , Marina Konopleva  2 , Shane Mitchell  3
Affiliations
Review

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Michael Wysota et al. Curr Oncol Rep. 2024 Apr.

Abstract

Purpose of review: This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).

Recent findings: Over the course of the last 5-6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients. Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.

Keywords: AML; Acute myeloid leukemia; Immune therapy; Molecular targets; Novel therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Novel therapeutics and their molecular targets which have been studied for treatment of acute myeloid leukemia
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Cancer stat facts: leukemia, acute myeloid leukemia (AML). National Cancer Institute, DCCPS, Surveillance Research Program. 2023. https://seer.cancer.gov/statfacts/html/amyl.html
    1. Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234–1244. doi: 10.1038/s41375-023-01884-2. - DOI - PMC - PubMed
    1. Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049–2061. doi: 10.1002/cncr.33458. - DOI - PMC - PubMed
    1. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. doi: 10.1038/s41408-021-00425-3. - DOI - PMC - PubMed
    1. DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032. doi: 10.1182/blood.2019001982. - DOI - PMC - PubMed